Functional MRI paradigm to aid CNS drug development
Boston, MA, March 16, 2015 –WorldCare Clinical (WCC), a leading provider of imaging services to the pharmaceutical and biotechnology industry, today announced that it has initiated collaboration with Massachusetts General Hospital (MGH) and the East West Integrative Medical Hospital and Research Institute (EWIMHRI) to develop and scale the MRI paradigm necessary to map brain functions during auditory and visual challenges. "Many neurodegenerative and psychiatric diseases alter cognition. Sponsors are looking for sensitive markers of changes in brain function to determine efficacy of many CNS drugs," stated Dr. Richard Walovitch, President of WCC. "To our knowledge we are the first imaging service provider to undertake this research challenge. We feel confident that combining the experience of the MGH clinical research team with our unique understanding of imaging paradigms will operationalize this paradigm for use in multi-center clinical trials."
About WorldCare Clinical
WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC’s robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.
For more information on WCC's services, please visit our website at worldcareclinical.com or contact: